From the Fatty Liver Alliance - In the MASH landscape, there is a strong, growing and passionate wave supporting the avoidance of biopsy for advanced liver disease assessment and a powerful argument for non-invasive liver health assessments.
"There's a desperate clinical need for a biomarker for this disease, and this was the premise for our study."
Oswald Quehenberger "and colleagues analyzed over 300 patient samples from a study on nonalcoholic steatohepatitis collected by the NASH Clinical Research Network to find such a biomarker. They reported on their work in the Journal of Lipid Research."
"After co-author Arun Sanyal of Virginia Commonwealth University gave a talk on fatty liver disease at a LIPID MAPS meeting, he collaborated with Edward Dennis and Quehenberger to search for noninvasive biomarkers for MASLD."
Predicting fatty liver disease from a tiny blood sample
------------------------------
Christopher Radka
Assistant Professor
University of Kentucky College of Medicine
Lexington KY
------------------------------